Jerry Weaver

473 total citations
16 papers, 244 citations indexed

About

Jerry Weaver is a scholar working on Hematology, Genetics and Oncology. According to data from OpenAlex, Jerry Weaver has authored 16 papers receiving a total of 244 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Hematology, 5 papers in Genetics and 4 papers in Oncology. Recurrent topics in Jerry Weaver's work include Acute Myeloid Leukemia Research (7 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (4 papers) and Chronic Lymphocytic Leukemia Research (2 papers). Jerry Weaver is often cited by papers focused on Acute Myeloid Leukemia Research (7 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (4 papers) and Chronic Lymphocytic Leukemia Research (2 papers). Jerry Weaver collaborates with scholars based in United States, France and Germany. Jerry Weaver's co-authors include Lorraine Yurkewicz, M. Ross Bullock, Lawrence F. Marshall, Lloyd Knapp, Reetta Kälviäinen, Martin J. Brodie, Patrick Kwan, G. M. Hochwald, Katsuaki Tanaka and J. G. Dunbar and has published in prestigious journals such as Blood, The Lancet Neurology and American Journal of Physiology-Heart and Circulatory Physiology.

In The Last Decade

Jerry Weaver

14 papers receiving 235 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jerry Weaver United States 6 84 73 68 64 61 16 244
Ulvi Vaher Estonia 9 55 0.7× 83 1.1× 91 1.3× 106 1.7× 50 0.8× 15 303
Vykuntaraju K. Gowda India 9 26 0.3× 104 1.4× 98 1.4× 96 1.5× 53 0.9× 79 334
Anna Jeong United States 12 58 0.7× 73 1.0× 38 0.6× 60 0.9× 112 1.8× 22 346
Kiyotaka Hashizume Japan 11 196 2.3× 150 2.1× 73 1.1× 31 0.5× 136 2.2× 28 395
Aurélie Hanin France 9 63 0.8× 139 1.9× 71 1.0× 60 0.9× 50 0.8× 24 236
Ann Hyslop United States 10 62 0.7× 143 2.0× 62 0.9× 20 0.3× 52 0.9× 21 279
Florian Sohm Austria 11 104 1.2× 43 0.6× 14 0.2× 45 0.7× 286 4.7× 15 378
Coral M. Stredny United States 10 51 0.6× 177 2.4× 130 1.9× 75 1.2× 39 0.6× 25 319
Adam L. Numis United States 7 47 0.6× 147 2.0× 142 2.1× 26 0.4× 53 0.9× 14 258
Moran Hausman‐Kedem Israel 8 53 0.6× 51 0.7× 25 0.4× 39 0.6× 26 0.4× 30 223

Countries citing papers authored by Jerry Weaver

Since Specialization
Citations

This map shows the geographic impact of Jerry Weaver's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jerry Weaver with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jerry Weaver more than expected).

Fields of papers citing papers by Jerry Weaver

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jerry Weaver. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jerry Weaver. The network helps show where Jerry Weaver may publish in the future.

Co-authorship network of co-authors of Jerry Weaver

This figure shows the co-authorship network connecting the top 25 collaborators of Jerry Weaver. A scholar is included among the top collaborators of Jerry Weaver based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jerry Weaver. Jerry Weaver is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
2.
Santini, Valeria, António Almeida, Aristoteles Giagounidis, et al.. (2020). Achievement of red blood cell transfusion independence in red blood cell transfusion-dependent patients with lower-risk non-del(5q) myelodysplastic syndromes correlates with serum erythropoietin levels. Leukemia & lymphoma. 61(6). 1475–1483. 4 indexed citations
3.
Stratton, John, et al.. (2019). Performance of Veterinary Services Pathway evolution and One Health aspects. Revue Scientifique et Technique de l OIE. 38(1). 291–302. 7 indexed citations
4.
Garcia‐Manero, Guillermo, António Almeida, Pierre Fenaux, et al.. (2018). Clinical Benefit-Risk Profile of Lenalidomide in Patients With Lower-risk Myelodysplastic Syndromes Without del(5q): Results of a Phase III Trial. Clinical Lymphoma Myeloma & Leukemia. 19(4). 213–219.e4. 3 indexed citations
5.
Seymour, J.F., Rena Buckstein, Valeria Santini, et al.. (2017). Azacitidine Versus Conventional Care Regimens (CCR) in Elderly Patients (≥75 Years) with Acute Myeloid Leukemia (AML) in the AZA-AML-001 Study. Leukemia Research. 55. S67–S68. 1 indexed citations
6.
Govindan, Ramaswamy, Manuel Cobo, Santiago Ponce Aix, et al.. (2017). MA 10.02 Nab-Paclitaxel + Durvalumab as Second- or Third-Line Treatment of Advanced NSCLC: Results from ABOUND.2L+. Journal of Thoracic Oncology. 12(11). S1839–S1840.
7.
Garcia‐Manero, Guillermo, Valeria Santini, António Almeida, et al.. (2016). Effect of Lenalidomide (LEN) Exposure on Response and Outcomes in Patients (Pts) with Lower-Risk Non-Del(5q) Myelodysplastic Syndromes (MDS). Blood. 128(22). 3190–3190. 1 indexed citations
8.
9.
Seymour, John F., Rena Buckstein, Valeria Santini, et al.. (2016). Efficacy and Safety of Azacitidine (AZA) Versus Conventional Care Regimens (CCR) in Patients Aged ≥75 Years with Acute Myeloid Leukemia (AML) in the Phase 3 AZA-AML-001 Study. Blood. 128(22). 2818–2818. 2 indexed citations
10.
11.
Weaver, Jerry, et al.. (2015). Strategies on Using Prior Information When Assessing Adverse Events. Statistics in Biopharmaceutical Research. 8(1). 106–115. 5 indexed citations
12.
Dhruva, Anand, Shelley R. Adler, Jerry Weaver, et al.. (2012). P05.18. Mixed methods approaches in whole systems research: a study of Ayurvedic diagnostics. BMC Complementary and Alternative Medicine. 12(S1). 1 indexed citations
13.
Kwan, Patrick, Martin J. Brodie, Reetta Kälviäinen, et al.. (2011). Efficacy and safety of pregabalin versus lamotrigine in patients with newly diagnosed partial seizures: a phase 3, double-blind, randomised, parallel-group trial. The Lancet Neurology. 10(10). 881–890. 67 indexed citations
14.
Yurkewicz, Lorraine, Jerry Weaver, M. Ross Bullock, & Lawrence F. Marshall. (2005). The Effect of the Selective NMDA Receptor Antagonist Traxoprodil in the Treatment of Traumatic Brain Injury. Journal of Neurotrauma. 22(12). 1428–1443. 98 indexed citations
15.
Uderman, Howard D., John J. Brennan, Carol L. Delaney, et al.. (1999). Fosinopril and Hydrochlorothiazide Combination versus Individual Components: Lack of a Pharmacokinetic Interaction. Annals of Pharmacotherapy. 33(5). 525–530. 2 indexed citations
16.
Marmarou, Anthony, G. M. Hochwald, Toru Nakamura, et al.. (1994). Brain edema resolution by CSF pathways and brain vasculature in cats. American Journal of Physiology-Heart and Circulatory Physiology. 267(2). H514–H520. 46 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ulvi Vaher Breakdown of academic impact, for papers by Vykuntaraju K. Gowda Breakdown of academic impact, for papers by Anna Jeong Breakdown of academic impact, for papers by Kiyotaka Hashizume Breakdown of academic impact, for papers by Aurélie Hanin Breakdown of academic impact, for papers by Ann Hyslop Breakdown of academic impact, for papers by Florian Sohm Breakdown of academic impact, for papers by Coral M. Stredny Breakdown of academic impact, for papers by Adam L. Numis Breakdown of academic impact, for papers by Moran Hausman‐Kedem
Rankless by CCL
2026